|
1.
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Hirayama A, Kami K, Sugimoto M, et al:
Quantitative metabolome profiling of colon and stomach cancer
microenvironment by capillary electrophoresis time-of-flight mass
spectrometry. Cancer Res. 69:4918–4925. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Zhou J, Schmid T, Schnitzer S and Brüne B:
Tumor hypoxia and cancer progression. Cancer Lett. 237:10–21. 2006.
View Article : Google Scholar
|
|
4.
|
Cummins EP and Taylor CT:
Hypoxia-responsive transcription factors. Eur J Physiol.
450:363–371. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Selvendiran K, Bratasz A, Kuppusamy ML, et
al: Hypoxia induces chemoresistance in ovarian cancer cells by
activation of signal transducer and activator of transcription 3.
Int J Cancer. 125:2198–2204. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Oh M-K, Park H-J, Kim N-H, et al:
Hypoxia-inducible factor-1α enhances haptoglobin gene expression by
improving binding of STAT3 to the promoter. J Biol Chem.
286:8857–8865. 2011.
|
|
7.
|
Ledoux S, Yang R, Friedlander G and
Laouari D: Glucose depletion enhances P-glycoprotein expression in
hepatoma cells: role of endoplasmic reticulum stress response.
Cancer Res. 63:7284–7290. 2003.PubMed/NCBI
|
|
8.
|
Cui H, Darmanin S, Natsuisaka M, et al:
Enhanced expression of asparagine synthetase under glucose-deprived
conditions protects pancreatic cancer cells from apoptosis induced
by glucose deprivation and cisplatin. Cancer Res. 67:3345–3355.
2007. View Article : Google Scholar
|
|
9.
|
Duan Z, Foster R, Bell DA, et al: Signal
transducer and activator of transcription 3 pathway activation in
drug-resistant ovarian cancer. Clin Cancer Res. 12:5055–5063. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Liu L, Ning X, Sun L, et al:
Hypoxia-inducible factor-1α contributes to hypoxia-induced
chemoresistance in gastric cancer. Cancer Sci. 99:121–128.
2008.
|
|
11.
|
Kendziorra E, Ahlborn K, Spitzner M, et
al: Silencing of the Wnt transcription factor TCF4 sensitizes
colorectal cancer cells to (chemo-) radiotherapy. Carcinogenesis.
32:1824–1831. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Lee AS: GRP78 induction in cancer:
therapeutic and prognostic implications. Cancer Res. 67:3496–3499.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Mathieu J, Zhang Z, Zhou W, et al: HIF
induces human embryonic stem cell markers in cancer cells. Cancer
Res. 71:4640–4652. 2011. View Article : Google Scholar
|
|
14.
|
Real PJ, Sierra A, Juan A, et al:
Resistance to chemotherapy via Stat3-dependent overexpression of
Bcl-2 in metastatic breast cancer cells. Oncogene. 21:7611–7618.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Forsythe JA, Jiang BH, Iyer NV, et al:
Activation of vascular endothelial growth factor gene transcription
by hypoxiainducible factor 1. Mol Cell Biol. 16:4604–4613.
1996.PubMed/NCBI
|
|
16.
|
Niu G, Wright KL, Huang M, et al:
Constitutive Stat3 activity up-regulates VEGF expression and tumor
angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar
|
|
17.
|
Hwang I, Kim J and Jeing S: β-catenin and
peroxisome proliferator-activated receptor-δ coordinate dynamic
chromatin loops for the transcription of vascular endothelial
growth factor A gene in colon cancer cells. J Biol Chem.
287:41364–41373. 2012.
|
|
18.
|
Rodda DJ, Chew J-L, Lim L-H, et al:
Transcriptional regulation of Nanog by OCT4 and SOX2. J Biol Chem.
280:24731–24737. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Izuishi K, Kato K, Ogura T, et al:
Remarkable tolerance of tumor cells to nutrient deprivation:
possible new biochemical target for cancer therapy. Cancer Res.
60:6201–6207. 2000.
|
|
20.
|
Korinek V, Barker N, Morin PJ, et al:
Constitutive transcriptional activation by a β-catenin-Tcf complex
in APC−/− colon carcinoma. Science. 275:1784–1787.
1997.
|
|
21.
|
Reed JC: Regulation of apoptosis by bcl-2
family proteins and its role in cancer and chemoresistance. Curr
Opin Oncol. 7:541–546. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Samuel S, Fan F, Dang LH, et al:
Intracrine vascular endothelial growth factor signaling in survival
and chemoresistance of human colorectal cancer cells. Oncogene.
30:1205–1212. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Loh Y-H, Ng J-H and Ng H-H: Molecular
framework underlying pluripotency. Cell Cycle. 7:885–891. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Chiou S, Wang M-L, Chou Y-T, et al:
Coexpression of Oct4 and Nanog enhances malignancy in lung
adenocarcinoma by inducing cancer stem cell-like properties and
epithelial-mesenchymal transdifferentiation. Cancer Res.
70:10433–10444. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Vaiopoulos AG, Kostakis ID, Koutsilieris M
and Papavassiliou AG: Concise review: colorectal cancer stem cells.
Stem Cells. 30:363–371. 2012. View Article : Google Scholar
|
|
26.
|
Kim J-W and Dang CV: Cancer’s molecular
sweet tooth and the Warburg effect. Cancer Res. 66:8927–8930.
2006.
|
|
27.
|
Kaelin WG Jr and Thompson CB: Clues from
cell metabolism. Nature. 465:562–564. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Liu X-W, Su Y, Zhu H, et al:
HIF-1α-dependent autophagy protects Hela cells from fenretinide
(4-HPR)-induced apoptosis in hypoxia. Pharmacol Res. 62:416–425.
2010.
|
|
29.
|
Jung JE, Lee H-G, Cho I-H, et al: STAT3 is
a potential modulator of HIF-1-mediated VEGF expression in human
renal carcinoma cells. FASEB J. 19:1296–1298. 2005.PubMed/NCBI
|
|
30.
|
Xu Q, Briggs J, Park S, et al: Targeting
Stat3 blocks both HIF-1 and VEGF expression induced by multiple
oncogenic growth signaling pathways. Oncogene. 24:5552–5560. 2005.
View Article : Google Scholar : PubMed/NCBI
|
